Workflow
长效C5补体抑制剂瑞利珠单抗获批上市
Qi Lu Wan Bao·2025-09-12 10:53

Core Viewpoint - AstraZeneca announced the official launch of Ultomiris® (Ravulizumab injection) in China, aimed at improving the quality of life for patients with generalized Myasthenia Gravis (gMG) and reducing relapses in patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) [1] Group 1 - Ultomiris® is a long-acting C5 complement inhibitor that will be used in combination with conventional treatment for adult gMG patients who are positive for anti-acetylcholine receptor (AChR) antibodies [1] - The drug is also indicated for adult NMOSD patients who are positive for anti-aquaporin-4 (AQP4) antibodies [1] - AstraZeneca's Vice President for Rare Diseases in China expressed optimism about the drug's potential to provide innovative treatment solutions for patients suffering from gMG and NMOSD [1]